# Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

> **NCT06640517** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Biocad** · enrollment: 140 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Netakimab
- **DRUG:** Placebo
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT06640517
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-08
- **Primary completion:** 2026-06
- **Final completion:** 2028-02
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06640517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06640517, "Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06640517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*